We have updated the Diabeter Research website with a number of publications of studies in which Diabeter, or employees of Diabeter, were involved

• Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the HypoMETRICS application. BMJ Open . 2022 Feb 1;12(2):e051651
  This paper describes the development of an app to record current or very recent hypoglycemia events in real-world settings.

 

• The Psychological Implications of Automated Insulin Delivery Systems in Type 1 Diabetes Care. Front. Clin. Diabetes Healthc., 03 May 2022
  Review on the psychological aspects around the use of (advanced) hybrid closed-loop insulin systems systems.

 

• A Systematic Review of Instruments Measuring the Division of Care Responsibilities between Children with Type 1 Diabetes and their Parents. Curr Diabetes Rev . 2022 May 10
  This paper provides an overview of instruments to measure the division of diabetes care responsibilities between parents and children.

 

• Improved glucometrics in people with type 1 diabetes 1 year into the COVID-19 pandemic. BMJ Open Diabetes Res Care . 2022 May;10(3):e002789
  Evaluation of glycemic parameters and associated factors 1 year after the start of the COVID-19 pandemic in a cohort of people with T1D.

 

•  Intralymphatic GAD-alum (Diamyd®) improves glycaemic control in Type 1 diabetes with HLA DR3-DQ2. 2022 Jun 6;dgac343.
  GAD-alum (Diamyd ®) is a vaccine in development for type 1 diabetes. The Diagnode-2 study, in which Diabeter participated, tested the efficacy of the vaccine. This publication reports on the efficacy in people with T1D with the HLA DR3-DQ2 genotype, who were earlier found to be more susceptible to the vaccine.